Natco Pharma’s net profit increased 40.1 per cent to ₹386 crore in the fourth quarter ended March 31, 2024 against ₹275 crore in the corresponding quarter of previous financial year.
The revenue of the Hyderabad-based company increased 19 per cent to ₹1,068 crore compared with ₹898 crore in the same period last year.
The drug-maker recorded a consolidated total revenue of ₹4,126.9 crore for the year ended on March 31, 2024, against ₹2,811 crore registering 46.8 per cent growth. The net profit for the period increased 94 per cent at ₹1,388 crore against ₹715 crore last year.
“The company has recorded its highest-ever consolidated revenue and profits during this financial year. This is the result of decades of our diligence. On the domestic business front, the company has taken a one-time charge of approximately ₹90 crore which is reflected in revenue and profitability numbers,’‘ Natco said in a release.
Also read: Adani Energy Solutions to raise ₹12,500 crore via QIP
There were three aspects of the one-time charge. In pharma formulations domestic business, Natco charged and accounted for a return of stock amounting to about ₹35 crore due to change in the business model. In the Crop Health Sciences (CHS) business, due to poor crop season the stock returns were more than expected by ₹25 crore. Provisions on assets of CHS division amounted to about ₹30 crore.
“This was done due to non-utilisation of certain assets used for manufacturing of Agro intermediates,’‘ the Hyderabad-based company said.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.